NCT05778318

Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Conditions

• COVID-19 Pneumonia

Interventions

Type	Name	Description
DRUG	The group of patients who received Lianhua Qingwen orally	Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
OTHER	The group of patients who did not receive Lianhua Qingwen orally	The group of patients who did not receive Lianhua Qingwen orally.

Timeline

• Start date: 2023-03-20
• Primary completion: 2024-04-30
• Completion: 2024-06-30
• First posted: 2023-03-21
• Last updated: 2023-05-11

Locations

1 site across 1 country: China